KEY TAKEAWAYS
- U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset better-than-expected quarterly results.
- The German company said it expects 2025 total revenues of between 1.7 billion euros ($1.8 billion) and 2.2 billion euros ($2.4 billion), below analysts’ projections compiled by Visible Alpha.
- Despite a tough start to 2025, the stock has gained about 9% in the past 12 months.
U.S.-listed shares of BioNTech (BNTX) lost ground Monday, as the COVID-19 vaccine maker’s soft outlook for the year offset better-than-expected quarterly results.
The German company said it expects 2025 total revenues of between 1.7 billion euros ($1.8 billion) and 2.2 billion euros ($2.4 billion). That is down from the 2.8 billion euros of revenue it posted for 2024 and lags the 2.4 billion euro consensus projection of analysts polled by Visible Alpha.
For the fourth quarter, BioNTech reported earnings per share (EPS) of 1.08 euros on revenue of 1.2 billion euros, down from EPS of 1.88 euros on revenue of 1.5 billion euros a year earlier, but ahead of analysts’ estimates.
BioNTech attributed the decline in revenues to lower sales of its COVID-19 vaccines as demand fell and write-downs by its partner Pfizer (PFE). BioNTech said the write-downs would continue to affect its outlook for the year.
BioNTech shares were down about 3% to $105.28 intraday Monday. Despite a tough start to 2025, they’ve gained about 9% in the past 12 months.
CORRECTION—March 10, 2025: This article has been corrected since it was first published to reflect earnings were reported in euros.
:max_bytes(150000):strip_icc()/GettyImages-2095975132-1c079bfff64b430192c32eaf0a5b3ac7.jpg?w=1200&resize=1200,0&ssl=1&description=BioNTech+Stock+Drops+as+Sales+Outlook+Disappoints){kind=link}